NON HODGKINS LYMPHOMA TREATMENT MARKET ANALYSIS
Non-Hodgkins lymphoma treatment market taxonomy:
On the basis of type of non-hodgkins lymphoma, the non-hodgkins lymphoma treatment market is classified into:
On the basis of end user, the non-hodgkins lymphoma treatment market is classified into:
Increase in incidence of NHL will fuel the market
By geography, North America holds the major share in the market because of the high incidence rate of blood cancers in the U.S. According to Leukemia and Lymphoma Society, non-Hodgkin lymphoma is the seventh most common cancer in the U.S. and fifth in the UK. The National Cancer Institute estimated 72,580 new cases and 20,150 deaths in 2016 due to NHL in the U.S. According to the American Cancer Society, 20 cases of NHL, 6 cases of myeloma and 13 cases of leukemia were estimated per 100,000 population in 2014 in the U.S. Moreover, the organization states that, around 6 out of 10 people diagnosed with non-Hodgkin lymphoma are aged 65 and above. Also, NHL is much more common in men than in women.
Need a Custom Report?
We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports
Customize Now
Credibility and Certifications
9001:2015
27001:2022
Joining thousands of companies around the world committed to making the Excellent Business Solutions.
View All Our Clients
U.S.: 
U.K. : 
India : 